Lundbeck Q3 2019 Financial Results

Abilify Maintena continues its robust growth Abilify Maintena sales* * Grew 23% (21% in L.C.) to DKK 1,457 million in 9M 2019 I (Quarterly DKKm) - * * Abilify Maintena is Lundbeck's best selling product in Europe LAI market continues double- digit growth to USD 3.8bn (9M) 600 1.500 North America +24% Int. Markets 500 Europe 1.200 400 Abilify Maintena's share of the LAI market is 17% compared to 16% in FY20181) 300 * Findings from PRELAPSE trial²) 200 to be presented at ACNP in December 1) Reported net sales of atypical LAIS 2) NCT02360319 8 100 0 Q3.17 Q3.18 900 600 300 Abilify Maintena sales* (9M - DKKM) +23% 0 Q3.19 9M.17 9M.18 9M.19 *) Lundbeck's share of revenue Lundbeck

View entire presentation